An FDA advisory panel voted 7-2 that Grail's Galleri blood test's benefits outweigh risks, with unanimous support for safety. Approval could come in months, giving Grail a lead over rivals Guardant Health and Abbott. Grail shares rose 35% ahead of the vote. Medicare coverage may follow in 2029.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
